Research & Education

IASLC Announces Advocacy Travel Awards: International lung cancer patient advocates may apply to receive grants for WCLC 2015 in Denver


DENVER – The International Association for the Study of Lung Cancer (IASLC) has opened the application process for lung cancer patient advocates to apply for Advocacy Travel Awards. Awardees receive a travel stipend, free conference registration, up to four nights’ accommodation, and a complimentary IASLC Membership for 2016.

NCI/FDA lung cancer workshop leads to the innovatively designed clinical trials Lung-MAP and ALCHEMIST, the first “Master Protocol” trials

DENVER – The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute (NCI) sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration (FDA), academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies.

Less costly to screen for and treat early-stage lung than to treat late-stage lung cancer.

DENVER – The average cost to screen high-risk individuals for developing lung cancer with low-dose computed tomography (LDCT) plus the average cost of curative intent treatment, like surgery, is lower than the average cost to treat advanced stage lung cancer, which quite rarely results in a cure.

Modest acute changes in cardiac biomarkers and electrocardiogram findings following thoracic radiation therapy.

DENVER – There were only modest acute changes in cardiac biomarkers and electrocardiograms and there were no clinically significant cardiac events in patients with high-dose radiation exposure to the heart following thoracic radiation therapy (RT) and short-term follow-up.

Abstracts for LALCA 2014 now published in the JTO.

DENVER – The International Association for the Study of Lung Cancer (IASLC) is pleased to announce that scientific abstracts for the 6th Latin American Conference on Lung Cancer (LALCA) are now available online through the Journal of Thoracic Oncology.

BIM deletion predicts survival in advanced non-small cell lung cancer.

DENVER – Bcl-2-like protein 11 (BIM) deletion in advanced non-small cell lung cancer (NSCLC) is associated with shorter progression free survival (PFS) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or chemotherapy treated Asian patients. Also, BIM deletion independently predicts overall survival (OS) of advanced NSCLC patients.